TruSight Oncology UMI Reagents

Error correction with unique molecular identifiers (UMIs) for next-generation sequencing libraries.Read More...
选择产品

TruSight Oncology UMI Reagents (16 indexes, 48 samples)

20024586

Accessory Products
What accessories do I need?

TruSight® Tumor 170 Content Set

20010188

TruSight cfDNA UMI for HiSeq 2500 (48 Samples)

20023394

TruSight cfDNA UMI for HiSeq 4000 (48 Samples)

20023395

TruSight cfDNA UMI for NovaSeq S2 (48 Samples)

20023396

Product Highlights

The TruSight Oncology UMI Reagents reduce background noise in sequencing data, enabling detection of low-frequency variants, such as those found in cell-free DNA (cfDNA).

Reduced Error Rates

Circulating tumor DNA (ctDNA) may represent a very small fraction of cfDNA, near the limit of detection for next-generation sequencing (NGS). The TruSight Oncology UMI Reagents address this challenge with UMIs and error correction software, reducing error rates to < 0.007% and enabling detection of low-frequency variants. Lower error rates increase analytical specificity, resulting in higher confidence in NGS data.

Integration into TruSight Oncology Workflow

The TruSight Oncology UMI Reagents include UMI adapters and indexes, plus TruSight Oncology DNA library prep and enrichment reagents. These reagents can also be paired with the TruSight Tumor 170 DNA oligos. Integration of UMIs does not create any extra steps in the library prep workflow.

Intuitive Software for Error Correction

The UMI Error Correction App aligns reads, then uses UMIs to exclude false positives, reducing variant calling errors. The UMI Error Correction App is available in the cloud-based BaseSpace Sequence Hub or for local installation.

Frequently Purchased Together

规格

Method-Specific Workflow Example

 

Supporting Data and Figures

Background Reduction Facilitates Accurate Variant Calling
Background Reduction Facilitates Accurate Variant Calling

To enable accurate detection of rare variants, UMIs are integrated with error correction software, enabling true mutations to be distinguished from background noise. The bottom panel illustrates how, by removing inherent errors that result in false positives, the reduced error rate allows true mutations (red dots) to be better distinguished from background noise (grey dots).

 
Reduction of Error Rates with UMIs
Sequencing Run Mean Error Rate (Uncollapsed Reads) Mean Error Rate (Collapsed Reads)
1 0.038% 0.0023%
2 0.043% 0.0024%
3 0.035% 0.0024%
4 0.084% 0.0019%

Library preparation was performed using the TruSight Oncology UMI Reagents paired with DNA content from the TruSight Tumor 170 DNA assay, and 31 samples were distributed among four independent sequencing runs on the HiSeq 4000 System. Mean error rates are shown with and without collapsed reads using the UMI Error Correction App.

Related Products

TruSight Oncology 500

此分析方法靶向多种变异类型,包括肿瘤突变负荷(TMB)和微卫星不稳定性(MSI),即使是低质量样本同样适用。


TruSight Oncology

TruSight Oncology是一组用于检测癌症变异的NGS平台试剂,能使用基于富集的方法来同时分析DNA和RNA。不包含基因内容。


BaseSpace Sequence Hub

通过功能强大的商业化计算环境进行数据的管理、分析和共享以简化生物信息学工作。


* Performance on the NovaSeq 6000 System was demonstrated but not extensively tested.